MediLink's interim phase III data show Tambotatug pelitecan improves overall survival in relapsed small-cell lung cancer, bolstering Roche's oncology prospects in China
Executive summary: MediLink released interim results from the phase III TAISHAN-302 trial showing that Tambotatug pelitecan (Tam-Peli) achieved significantly improved overall survival compared to topotecan in Chinese patients with relapsed small-cell lung cancer. The outcome suggests a potential new therapeutic option for a hard-to-treat cancer, which could enhance Roche's oncology portfolio in China and affect the competitive landscape for small-cell lung cancer treatments.
Who is involved: Roche, MediLink, Chinese patients with relapsed small-cell lung cancer enrolled in the TAISHAN-302 trial, and the trial investigators.
Likely next: MediLink will continue to analyse the TAISHAN-302 data and determine subsequent development steps for Tam-Peli, including potential regulatory discussions with China's NMPA.
Roche's collaborator MediLink announced interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Peli (tambotatug pelitecan, YL201) versus topotecan in Chinese patients with relapsed small-cell lung cancer. The data indicate a significantly improved overall survival endpoint, suggesting a potential new treatment option for a disease with limited therapies. This advancement could strengthen Roche's oncology pipeline in the Chinese market and influence future development decisions for Tam-Peli. No safety concerns or specific efficacy percentages were disclosed in the release.
Timeline
- — Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer (GlobeNewswire)
Analysis — what this means
Sectors affected
- small-cell lung cancer therapeutics
- oncology
- biopharma
Key entities
Sources
Related cases
- Ascletis initiates dosing in a global Phase III trial of its oral GLP-1 agonist ASC30 for chronic weight management, aiming to challenge injectable obesity therapies
- U.S. Air Force selects LGNDX for Phase III deployment of its defense acquisition platform, validating the company's mission software for wider DoD adoption
- Politico Europe’s Machthaber podcast profiles Charles III as a focal point for understanding global power dynamics and decision-making
- InnoCare’s TYK2 inhibitor fadeucravacitinib (ICP-488) met the primary endpoint in its Phase III psoriasis trial, advancing the drug toward regulatory submission
- Roche posts 6% currency‑adjusted growth while core EPS slips 2% as a strong franc trims headline sales
- Roche promotes Foundation Medicine chief to lead its North American diagnostics unit, reinforcing internal talent pipeline